Becton Dickinson (BDX) has initiated several voluntary Class I sub-recalls of BD Spinal Tray products across the US after FDA inspections flagged acceptance testing deficiencies at a supplier of bupivacaine in dextrose.

Becton Dickinson's share price has been under pressure, with the stock down 26.14% on a year to date share price return and 6.59% over 90 days, even though the 1 year total shareholder return is 11.34%. This suggests momentum has softened recently as investors reassess risk around product quality and operational execution.

If this recall has you thinking more broadly about healthcare and technology in medicine, it could be a useful moment to see what else is on the move through 41 healthcare AI stocks

With Becton Dickinson shares under pressure and trading at a discount to some valuation estimates, the key question for investors is whether sentiment has swung too far or if the market is correctly pricing in future growth.

Most Popular Narrative: 20.6% Undervalued

Becton Dickinson last closed at $143.98, while the most followed narrative anchors fair value at $181.23, framing a sizeable valuation gap for investors to interrogate.

The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue), enabling higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.

Want to see what sits behind that fair value gap? The narrative leans on tighter margins, steadier cash generation, and a premium earnings multiple that is anything but conservative.

Result: Fair Value of $181.23 (UNDERVALUED)

However, there are clear risks to this Becton Dickinson narrative, including ongoing tariff and trade pressures, as well as execution challenges around the recent Biosciences and Diagnostics separation.

Next Steps

After considering both the risks and rewards around Becton Dickinson, do you feel the caution or the opportunity stands out more strongly right now? Act while the information is fresh in mind and review the balance of potential upsides and concerns through 6 key rewards and 2 important warning signs

Looking for more investment ideas beyond Becton Dickinson?

If you want to stress test your view on Becton Dickinson and avoid missing other opportunities, use this moment to scan fresh ideas across different styles and risk levels.

• Target dependable cash generators by checking stocks in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with resilient fundamentals.
• Hunt for potential mispricings by reviewing companies in the screener containing 20 high quality undiscovered gems that may not yet be on most investors' radars.
• Focus on capital preservation by assessing companies in the 66 resilient stocks with low risk scores that score well on resilience and risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.